Geron CorporationNASDAQ: GERN

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

· Issued by Geron Corporation via Business Wire

Summary by 6ix

Kahn Swick & Foti, LLC (KSF), a securities litigation law firm, has started an investigation into Geron Corporation. It is looking at whether Geron's officers and/or directors breached their fiduciary duties (legal duties to act in shareholders' interests) or otherwise broke state or federal laws.

Key details

  • KSF says that throughout 2024 Geron promoted the revenue outlook and expected growth of its main product, imetelstat, a cancer drug sold under the brand name Rytelo.
  • According to KSF, Geron's results for the fourth quarter of fiscal 2024, released on February 26, 2025, said Rytelo's growth had flattened in prior months due to seasonality, competition, lack of awareness and the burden of the drug's required monitoring.
  • Geron and certain of its executives were later sued in a securities class action lawsuit (a case brought on behalf of a group of investors) alleging they failed to disclose material information in violation of federal securities laws.
  • KSF is asking people with relevant information, and long-term holders of Geron shares, to contact the firm at no cost.

What’s still pending

  • The securities class action lawsuit against Geron and certain of its executives remains ongoing.

6ix wrote this summary from the release below and checked it against the release.

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS: GERN).

Throughout 2024, the Company touted the revenue outlook and anticipated growth of its primary product, imetelstat, a telomerase inhibitor that it sells under the brand name, Rytelo, designed to reduce the proliferation of malignant cells to permit the production of new healthy cells. On February 26, 2025, the Company announced its financial results for the fourth quarter of fiscal 2024, disclosing that the growth of Rytelo had flattened over the prior months due to seasonality, competition, lack of awareness, and the burden of the monitoring requirement necessary for the drug treatment.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether Geron’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Geron shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3606 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-gern/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View original source (Business Wire)Company analysis

Earlier from Geron

All Geron news releases